orelabrutinib
orelabrutinib: sourced relationships with 1 company · 7 clinical trials tracked.
orelabrutinib evidence translation
What we can confirm
7 tracked trials
What it means
What to watch
Prepared research question
How could orelabrutinib → ZBIO affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Zenas BioPharma, Inc. (ZBIO) Secondary Progressive Multiple Sclerosis; Multiple Sclerosis… | Phase 3 |
Clinical Trial Registry Records (7)
A Randomized, Multicenter, Open-label, Phase 3 Study to Compare ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL)
Primary endpoint: Progression-free survival (PFS) as assessed by Independent Review Committee (IRC).
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Primary Progressive Multiple Sclerosis
Primary endpoint: Time to onset of composite confirmed disability progression (cCDP) , confirmed over at least 12 weeks (12-week cCDP)
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Non-active Secondary Progressive Multiple Sclerosis
Primary endpoint: Time to onset of confirmed disability progression (CDP) events, confirmed over at least 24 weeks
A Multicenter, Open-Label, Single-Arm, Prospective Clinical Study of PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) in the Treatment of Newly Diagnosed Primary Central Nervous System Lymphoma (ND-PCNSL) and Secondary Central Nervous System Lymphoma (SCNSL)
Primary endpoint: 1 year Progression free survival (PFS)
A Phase II/III Study of ICP-248 in Combination With Orelabrutinib in Patients With Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Primary endpoint: Adverse events (AEs) and serious adverse events (SAEs) evaluation according to CTCAE V5.0 or iwCLL 2018 criteria
A Randomized, Controlled, Open-label, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Orelabrutinib Plus Rituximab Versus Lenalidomide Plus Rituximab in Relapsed/Refractory Marginal Zone Lymphoma
Primary endpoint: IRC-assessed PFS
A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma
Primary endpoint: PFS
Frequently asked questions
Which companies have sourced relationships with orelabrutinib?
orelabrutinib has dated SEC/FDA relationship records for Zenas BioPharma, Inc..
How many clinical trials involve orelabrutinib?
BioSniper tracks 7 clinical trials involving orelabrutinib.